NCT00568503View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
COPD
Interventions
DRUG

QAX028

DRUG

Placebo

DRUG

Tiotropium bromide

DRUG

QAX028

DRUG

QAX028

Trial Locations (1)

Unknown

Novartis Investigator Site, Birkeroed

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY